Literature DB >> 15181614

A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans.

Richard K Sterling1, R Todd Stravitz, Velimir A Luketic, Arun J Sanyal, Melissa J Contos, A Scott Mills, Mitchell L Shiffman.   

Abstract

BACKGROUND & AIMS: Differences in hepatitis C virus (HCV)-related liver disease between Caucasians and African Americans remain controversial.
METHODS: We performed a retrospective analysis of 302 consecutive inmates in the Virginia Department of Corrections evaluated for HCV between October 1998 and July 2002. All subjects were anti-HCV positive, HCV treatment naive, human immunodeficiency virus and HBV negative, and had compensated liver disease.
RESULTS: The mean age of the cohort was 41 years; they were 91% male and 51% Caucasian. The mean ALT level was 94 U/L, 49% had a normal ALT level, and 80% were genotype 1. The mean Knodell histologic activity index (HAI) was 7.03, with bridging fibrosis in 18% and cirrhosis in 6%. When analyzed by race, the mean ALT level (106 vs. 79 U/L; P = 0.01), proportion with normal ALT level (46% vs. 57%; P = 0.06), and proportion with genotype 1 (67% vs. 94%; P < 0.001) were different between Caucasians and African Americans, respectively. Although the HAI and proportion with bridging fibrosis/cirrhosis were similar between groups, African Americans had lower piecemeal necrosis (1.41 vs. 1.72; P = 0.034) and fibrosis (1.12 vs. 1.40; P = 0.047) scores compared to Caucasians. Multivariate analysis demonstrated that age, ALT, and race were significant independent variables associated with total HAI, piecemeal necrosis, and fibrosis scores.
CONCLUSIONS: Although the overall spectrum of liver disease is similar, African Americans have less piecemeal necrosis and lower fibrosis scores independent of age and ALT compared with Caucasians.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181614     DOI: 10.1016/s1542-3565(04)00164-8

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  22 in total

1.  Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.

Authors:  Varun Saxena; Jennifer C Lai; Jacqueline G O'Leary; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; James F Trotter; Kartik Krishnan; Norah A Terrault
Journal:  Liver Transpl       Date:  2012-05       Impact factor: 5.799

2.  Impact of donor and recipient race on survival after hepatitis C-related liver transplantation.

Authors:  Jennifer E Layden; Scott J Cotler; Shellee A Grim; Michael J Fischer; Michael R Lucey; Nina M Clark
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

3.  Racial differences in fibrosis progression after HCV-related liver transplantation.

Authors:  Jennifer E Layden; Scott Cotler; Kimberly A Brown; Michael R Lucey; Helen S Te; Sheila Eswaran; Claus Fimmel; Thomas J Layden; Nina M Clark
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

4.  Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.

Authors:  Christine U Oramasionwu; Angela Dm Kashuba; Sonia Napravnik; David A Wohl; Lu Mao; Adaora A Adimora
Journal:  World J Hepatol       Date:  2016-03-08

5.  Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment.

Authors:  Monica M Pradhan; Ronald Horswell; Glenn Jones; Jennifer L Ramsey; William Cassidy
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

6.  Demographics of a large cohort of urban chronic hepatitis C patients.

Authors:  Firdous A Siddiqui; Murray N Ehrinpreis; James Janisse; Ravi Dhar; Elizabeth May; Milton G Mutchnick
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

7.  Effect of HIV on liver fibrosis among HCV-infected African Americans.

Authors:  D Silver; G Karnik; A Osinusi; R Silk; L Stabinski; L Doonquah; S Henn; G Teferi; H Masur; S Kottilil; D Fishbein
Journal:  Clin Infect Dis       Date:  2013-02-01       Impact factor: 9.079

8.  Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Authors:  Norah A Terrault; Kelly Im; Ross Boylan; Peter Bacchetti; David E Kleiner; Robert J Fontana; Jay H Hoofnagle; Steven H Belle
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

9.  Upper gastrointestinal hemorrhage: have new therapeutics made a difference?

Authors:  Chad T Whelan; Peter Kaboli; Qi Zhang; Juned Siddique; Siqin Ye; David O Meltzer
Journal:  J Hosp Med       Date:  2009-09       Impact factor: 2.960

Review 10.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.